Exelixis, Inc. Says Quickly Filled Spots in Cancer Trial

January 11, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SAN FRANCISCO, Jan 10 (Reuters) - Exelixis Inc (EXEL.O: Quote, Profile, Research) said it quickly attracted patients with non-small cell lung cancer for a trial of its experimental cancer drug XL647, Chief Executive George Scangos said on Thursday.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2

Exelixis, Inc.